The INSURE Study (INSIGHT MM, UVEA-IXA, REMIX): A Pooled Analysis of RRMM treated with IRd
MYELOMA CLINICAL TRIALS - Completed




- Dec 11, 2021
Meta-Analysis of Ciltacabtagene Autoleucel Versus Physicianās Choice in the Treatment of RRMM


- Dec 9, 2020
NCT04671251: Phase 1b Study of AEVI-007 in Subjects With Relapsed or Refractory Multiple Myeloma


- Dec 2, 2020
NCT04436029: Phase 2: Descartes-11 Consolidation Treatment Patients With High-Risk Multiple Myeloma


- Jul 11, 2020
Response-adapted lenalidomide maintenance in newly diagnosed myeloma: phase III GMMG-MM5 trial


- Dec 20, 2019
The MAMMOTH study: Monoclonal Antibodies in Multiple Myeloma: Outcomes after Therapy Failure


- Dec 30, 2018
NCT03665155: Phase 1/2 - PET Imaging MM with 89Zr-DFO-daratumumab, a CD38-targeting Monoclonal Ab


- Dec 22, 2018
NCT03489525: Phase 1: MEDI2228 in Subjects With Relapsed/Refractory Multiple Myeloma (MEDI2228)


- Dec 7, 2018
NCT03448978: Phase 1/2 - Descartes-08 - anti-BCMA-CAR-mRNA-trans. auto CD8+ T cells in Myeloma


- Dec 6, 2018
NCT03464916: Phase 1: Study to Evaluate the Safety and Efficacy of Anti-CD38 CAR-T in RRMM


- Dec 22, 2017
Post-transplant consolidation plus lenalidomide maintenance vs lenalidomide maintenance alone


- Dec 14, 2017
Phase II HOVON 143 Study: Ixazomib, Dara and Low Dose Dex in Intermediate-Fit Patients NDMM


- Dec 13, 2017
NCT03288493: Phase 1/2 - P-BCMA-101 Tscm CAR-T Cells in the Treatment of Patients With Myeloma


- Dec 15, 2016
NCT02951819: Phase 2 - Evaluate Dara-CyBorD in Previously Untreated and RRMM - LYRA


- Dec 9, 2016
NCT02728102: Phase 2 - Dendritic Cell/Myeloma Fusion Vaccine for Multiple Myeloma (BMT CTN 1401)


- Dec 9, 2016
NCT02655458: Phase 1 - Elotuzumab in Comb. With Auto transplant and Lenalidomide Maintenance in MM


- Dec 3, 2016
NCT02786511: Longterm Follow-up of Subjects Treated With bb2121


- Dec 30, 2015
NCT02336815 : Phase 2 - Selinexor Treatment of Refractory Myeloma (STORM)


- Dec 18, 2015
NCT02612779: Phase 2 - Elotuzumab in Combination With Pomalidomide and Low dose Dex Vs Nivo/Elo


- Dec 9, 2015
NCT02546167: Phase 1 - CART-BCMA Cells for Multiple Myeloma


- Dec 4, 2015
NCT02412878: Phase 3 - Once-weekly vs Twice-weekly Carfilzomib With Dexa in Relapsed MM (ARROW)


- Dec 3, 2015
NCT02406144: Phase 3 - GEM2014MAIN - Maintenance Len, Dex VS Len, Dex. & MLN9708 After ASCT NDMM


- Dec 1, 2015
NCT02514239: Phase 1 - Dose Escalation of i.v. BI 836909 Monotherapy in Last Line Myeloma Patients


- Dec 16, 2014
NCT02064387: Phase 1 -Safety Pharm.kinetics Pharm.dynamics Img. & Cl. Activity GSK2857916 - DREAMM-1


- Dec 14, 2014
NCT02046070: Phase 2 to Evaluate the Oral Ixazomib (MLN9708) With Cyclophosphamide & Dex Myeloma


- Dec 13, 2014
NCT02045017: Phase 2: Efficacy & Safety of Pom and Dex in RRMM Patients With Renal Insufficiency


- Dec 10, 2014
NCT02215967: Phase 1 - Study of T Cells Targeting B-Cell Maturation Antigen for RRMM


- Dec 9, 2014
NCT02322320: Phase 3 - Continued, Long-Term Follow-Up and Lenalidomide Maint. (BMT CTN 07LT)


- Dec 3, 2014
NCT02252263: Phase 1: Elotuzumab (BMS-901608) With Lirilumab (BMS-986015) or Urelumab (BMS-663513)


- Dec 20, 2013
NCT01794520: Phase 1/2: Study Evaluating ABT-199 in Participants With Relapsed or Refractory MM


- Dec 19, 2013
NCT01985126: Phase 2 - Dara in MM who had 3 prior lines inc. PI, Imid - or db. ref. MMY2002 (SIRIUS)


- Dec 14, 2013
NCT01980589: Phase 1b: Study of Carfilzomib, Cyclophosphamide and Dexamethasone in NDMM CHAMPION 2


- Dec 13, 2013
NCT01782963: Phase 2 - Lenalidomide/Bortezomib/Dexamethasone for Multiple Myeloma (MM) (RVD Lite)


- Dec 6, 2013
NCT02002598 : Phase 1 /2 -Carfilzomib + Bendamustine and Dex in New MM


- Dec 6, 2013
NCT01775553: Phase 2- High Dose Carfilzomib in Myeloma Patients Who Have Progressed On Standard Dose


- Dec 5, 2013
NCT01916252: Phase 3 - Bortezomib, Lenalidomide & IV Busulfan Under 65 - (GEM2012MENOS65) PETHEMA

